Karyopharm rises on FDA's 'fast track' tag for rare blood cancer treatment

Karyopharm Therapeutics

17/07/2023 21:28

** Shares of drug developer Karyopharm Therapeutics Inc
 KPTI.O  rise 7.19% to $1.64 after the bell
    ** The US Food and Drug Administration (FDA) grants 'fast
track' tag to Karyopharm's selinexor for the treatment of
patients with a rare type of bone marrow cancer known as
myelofibrosisis
    ** Top-line data from a late-stage study assessing the
efficacy and safety of once-weekly selinexor 60 mg in
combination with Incyte Corp's  INCY.O  Jakafi in a type of
patients with myelofibrosisis is expected in 2025
     ** Myelofibrosis is a rare type of blood cancer where scar
tissue forms in the bone marrow that disrupts the body's normal
production of blood cells
    ** The fast-track designation facilitates development and
expedites review of drug candidates intended to treat serious
conditions
    ** Stock down ~55% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))